Skip to main content
. 2023 Mar 17;16(3):455. doi: 10.3390/ph16030455

Figure 5.

Figure 5

Figure 5

Reporting odds ratio of ADRs referring to DOAC overdose: (a) dabigatran—AC and antiplatelet drugs; (b) rivaroxaban—AC and antiplatelet drugs; (c) apixaban—AC and antiplatelet drugs; (d) edoxaban—AC and antiplatelet drugs. ABC—abciximab; ACL—combination of acetylsalicylic acid and clopidogrel; ACE—acenocoumarol; API—apixaban; ARG—argatroban; BEM—bemiparin; BIV—bivalirudin; CER—certoparin; CIL—cilostazol; CLO—clopidogrel; DAB—dabigatran; DAL—dalteparin; DAN—danaparoid; DAS—combination of dipyridamole and acetylsalicylic acid; DIP—dipyridamole; EDO—edoxaban; ENO—enoxaparin; EPT—eptifibatide; FLU—fluindione; FON—fondaparinux; HEP—unfractionated heparin; LEP—lepirudin; NAD—nadroparin; PRA—prasugrel; RIV—rivaroxaban; TCL—ticagrelor; TIC—ticlopidine; TIN—tinzaparin; TIR—tirofiban; WAR—warfarin; * p <0.05; ** p ≤ 0.01; p ≤ 0.001; **** p ≤ 0.0001.